Gaede P H, Jepsen P V, Parving H H, Pedersen O B
Steno Diabetes Center.
Ugeskr Laeger. 1999 Jul 26;161(30):4277-85.
We carried out a randomized trial of stepwise intensive treatment or standard treatment of risk factors in patients with type 2 diabetes and microalbuminuria. Patients were allocated standard treatment (n = 80) or intensive treatment (n = 80). Intensive treatment was a stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria. The primary endpoint was development of nephropathy. Secondary endpoints were incidence or progression of diabetic retinopathy and neuropathy. Patients were followed for 3.8 years. The intensive group had significantly lower rates of progression to hephropathy (odds ratio 0.27 [95% CI 0.10-0.75]), progression of retinopathy (0.45 (0.21-0.95]), and progression of autonomic neuropathy (0.32 [0.12-0.78]). In conclusion, intensified multifactorial intervention in patients with type 2 diabetic mellitus and microalbuminuria has beneficial effects on long-term complications.
我们对2型糖尿病合并微量白蛋白尿患者的危险因素进行了逐步强化治疗或标准治疗的随机试验。患者被分配接受标准治疗(n = 80)或强化治疗(n = 80)。强化治疗是对行为改变、针对高血糖、高血压、血脂异常和微量白蛋白尿的药物治疗进行逐步实施。主要终点是肾病的发生。次要终点是糖尿病视网膜病变和神经病变的发生率或进展。患者随访3.8年。强化治疗组肾病进展率(优势比0.27 [95%可信区间0.10 - 0.75])、视网膜病变进展率(0.45 [0.21 - 0.95])和自主神经病变进展率(0.32 [0.12 - 0.78])显著更低。总之,对2型糖尿病合并微量白蛋白尿患者进行强化多因素干预对长期并发症有有益影响。